247 related articles for article (PubMed ID: 26052898)
1. Exercise Regulation of Marrow Fat in the Setting of PPARγ Agonist Treatment in Female C57BL/6 Mice.
Styner M; Pagnotti GM; Galior K; Wu X; Thompson WR; Uzer G; Sen B; Xie Z; Horowitz MC; Styner MA; Rubin C; Rubin J
Endocrinology; 2015 Aug; 156(8):2753-61. PubMed ID: 26052898
[TBL] [Abstract][Full Text] [Related]
2. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo.
Lecka-Czernik B; Ackert-Bicknell C; Adamo ML; Marmolejos V; Churchill GA; Shockley KR; Reid IR; Grey A; Rosen CJ
Endocrinology; 2007 Feb; 148(2):903-11. PubMed ID: 17122083
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow fat accumulation accelerated by high fat diet is suppressed by exercise.
Styner M; Thompson WR; Galior K; Uzer G; Wu X; Kadari S; Case N; Xie Z; Sen B; Romaine A; Pagnotti GM; Rubin CT; Styner MA; Horowitz MC; Rubin J
Bone; 2014 Jul; 64():39-46. PubMed ID: 24709686
[TBL] [Abstract][Full Text] [Related]
4. Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice.
Li M; Pan LC; Simmons HA; Li Y; Healy DR; Robinson BS; Ke HZ; Brown TA
Bone; 2006 Oct; 39(4):796-806. PubMed ID: 16759917
[TBL] [Abstract][Full Text] [Related]
5. Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.
Liu LF; Purushotham A; Wendel AA; Belury MA
Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1671-82. PubMed ID: 17322064
[TBL] [Abstract][Full Text] [Related]
6. A High Fat Diet Increases Bone Marrow Adipose Tissue (MAT) But Does Not Alter Trabecular or Cortical Bone Mass in C57BL/6J Mice.
Doucette CR; Horowitz MC; Berry R; MacDougald OA; Anunciado-Koza R; Koza RA; Rosen CJ
J Cell Physiol; 2015 Sep; 230(9):2032-7. PubMed ID: 25663195
[TBL] [Abstract][Full Text] [Related]
7. Exercise Regulation of Marrow Adipose Tissue.
Pagnotti GM; Styner M
Front Endocrinol (Lausanne); 2016; 7():94. PubMed ID: 27471493
[TBL] [Abstract][Full Text] [Related]
8. Structurally-diverse, PPARγ-activating environmental toxicants induce adipogenesis and suppress osteogenesis in bone marrow mesenchymal stromal cells.
Watt J; Schlezinger JJ
Toxicology; 2015 May; 331():66-77. PubMed ID: 25777084
[TBL] [Abstract][Full Text] [Related]
9. Exercise Decreases Marrow Adipose Tissue Through ß-Oxidation in Obese Running Mice.
Styner M; Pagnotti GM; McGrath C; Wu X; Sen B; Uzer G; Xie Z; Zong X; Styner MA; Rubin CT; Rubin J
J Bone Miner Res; 2017 Aug; 32(8):1692-1702. PubMed ID: 28436105
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone decreases bone mass and bone marrow fat.
Harsløf T; Wamberg L; Møller L; Stødkilde-Jørgensen H; Ringgaard S; Pedersen SB; Langdahl BL
J Clin Endocrinol Metab; 2011 May; 96(5):1541-8. PubMed ID: 21367933
[TBL] [Abstract][Full Text] [Related]
11. The tumour suppressor CDKN2A/p16
Wouters K; Deleye Y; Hannou SA; Vanhoutte J; Maréchal X; Coisne A; Tagzirt M; Derudas B; Bouchaert E; Duhem C; Vallez E; Schalkwijk CG; Pattou F; Montaigne D; Staels B; Paumelle R
Diab Vasc Dis Res; 2017 Nov; 14(6):516-524. PubMed ID: 28868898
[TBL] [Abstract][Full Text] [Related]
12. Daily leptin blunts marrow fat but does not impact bone mass in calorie-restricted mice.
Devlin MJ; Brooks DJ; Conlon C; Vliet Mv; Louis L; Rosen CJ; Bouxsein ML
J Endocrinol; 2016 Jun; 229(3):295-306. PubMed ID: 27340200
[TBL] [Abstract][Full Text] [Related]
13. Lipocalin 2 is a selective modulator of peroxisome proliferator-activated receptor-gamma activation and function in lipid homeostasis and energy expenditure.
Jin D; Guo H; Bu SY; Zhang Y; Hannaford J; Mashek DG; Chen X
FASEB J; 2011 Feb; 25(2):754-64. PubMed ID: 20974668
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone disrupts endosteal bone formation during distraction osteogenesis by local adipocytic infiltration.
Liu L; Aronson J; Lecka-Czernik B
Bone; 2013 Jan; 52(1):247-58. PubMed ID: 23069375
[TBL] [Abstract][Full Text] [Related]
15. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
Larsen PJ; Lykkegaard K; Larsen LK; Fleckner J; Sauerberg P; Wassermann K; Wulff EM
Eur J Pharmacol; 2008 Oct; 596(1-3):173-9. PubMed ID: 18761337
[TBL] [Abstract][Full Text] [Related]
16. Strain-specific effects of rosiglitazone on bone mass, body composition, and serum insulin-like growth factor-I.
Ackert-Bicknell CL; Shockley KR; Horton LG; Lecka-Czernik B; Churchill GA; Rosen CJ
Endocrinology; 2009 Mar; 150(3):1330-40. PubMed ID: 18948404
[TBL] [Abstract][Full Text] [Related]
17. Partial agonist, telmisartan, maintains PPARγ serine 112 phosphorylation, and does not affect osteoblast differentiation and bone mass.
Kolli V; Stechschulte LA; Dowling AR; Rahman S; Czernik PJ; Lecka-Czernik B
PLoS One; 2014; 9(5):e96323. PubMed ID: 24810249
[TBL] [Abstract][Full Text] [Related]
18. PPARγ partial agonist GQ-16 strongly represses a subset of genes in 3T3-L1 adipocytes.
Milton FA; Cvoro A; Amato AA; Sieglaff DH; Filgueira CS; Arumanayagam AS; de Lima Mdo C; Pitta IR; de Assis Rocha Neves F; Webb P
Biochem Biophys Res Commun; 2015 Aug; 464(3):718-23. PubMed ID: 26168725
[TBL] [Abstract][Full Text] [Related]
19. Different effects of pioglitazone and rosiglitazone on lipid metabolism in mouse cultured liver explants.
Djaouti L; Jourdan T; Demizieux L; Chevrot M; Gresti J; Vergès B; Degrace P
Diabetes Metab Res Rev; 2010 May; 26(4):297-305. PubMed ID: 20503262
[TBL] [Abstract][Full Text] [Related]
20. Blood glucose-lowering nuclear receptor agonists only partially normalize hepatic gene expression in db/db mice.
Loffler M; Bilban M; Reimers M; Waldhäusl W; Stulnig TM
J Pharmacol Exp Ther; 2006 Feb; 316(2):797-804. PubMed ID: 16260581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
